Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

ABSTRACT: Phase II, multicenter, open-label, multi-cohort proof-of-concept study designed to evaluate the safety and efficacy of Ezabenlimab combined with BI 907828 in patients with unresectable, locally advanced or metastatic solid tumors.

DISEASE(S): Sarcoma,Biliary Tract Cancer,Triple Negative Breast Neoplasms,Biliary Tract Neoplasms,Colorectal Cancer,Non Small Cell Lung Cancer,Triple Negative Breast Cancer,Tertiary Lymphoid Structures,Adult Soft Tissue Sarcoma

PROVIDER: 109483 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR